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Abstract 
Human cells that suffer mild DNA damage can enter a reversible state of growth arrest 
known as quiescence. This decision to temporarily exit the cell cycle is essential to prevent 
the propagation of mutations and most cancer cells harbour defects in the underlying control 
system. Here we present a mechanistic mathematical model to study the proliferation-
quiescence decision in non-transformed human cells. We show that two bistable switches, 
the restriction point (RP) and the G1/S transition, mediate this decision by integrating DNA 
damage and mitogen signals. In particular, our data suggests that the cyclin-dependent 
kinase inhibitor p21 (Cip1/Waf1), which is expressed in response to DNA damage, promotes 
quiescence by blocking positive feedback loops that facilitate G1 progression downstream of 
serum stimulation. Intriguingly, cells exploit bistability in the RP to convert graded p21 and 
mitogen signals into an all-or-nothing cell cycle response. The same mechanism creates a 
window of opportunity where G1 cells that have passed the RP can revert to quiescence if 
exposed to DNA damage. We present experimental evidence that cells gradually lose this 
ability to revert to quiescence as they progress through G1 and that the onset of rapid p21 
degradation at the G1/S transition prevents this response altogether, insulating S-phase from 
mild, endogenous DNA damage. Thus, two bistable switches conspire in the early cell cycle 
to provide both sensitivity and robustness to external stimuli. 
 
Significance 
Controlled transitions of human cells between proliferating and non-proliferating states are 
essential for normal development and tissue homeostasis. To understand how the decision to 
proliferate is made in response to positive input from growth factors and negative input from 
the DNA damage response, we have built a mathematical model of the underlying molecular 
network, based on data from live-cell imaging experiments. Our model suggests that two 
major cell cycle transitions are crucial for decision making: the restriction point, which 
integrates pro- and anti-proliferative signals, and the G1/S transition, which temporarily 
insulates cells from some aspects of the DNA damage response. Together, our model gives 
mechanistic insight into how cells maintain both sensitivity and robustness to external 
signals. 
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Introduction 
Living systems strive to proliferate and to protect their genomic information from harm. On 
the cellular level, these two aims have to be balanced to avoid the accumulation of 
deleterious mutations that can lead to cell death or cancer. Therefore, cells have evolved 
mechanisms to postpone proliferation in response to DNA damage. In particular, they can 
enter a reversible state of growth arrest after mitosis known as quiescence (1), which 
provides time for DNA repair and prevents the propagation of damage to future generations. 
Yet, how and when the decision between proliferation and quiescence is made, and how 
decision-making is implemented on a molecular level, remains elusive. 
Cell proliferation is regulated by a series of steps known as the cell cycle, which is driven by 
cyclin-dependent kinases (Cdks) and their regulatory counterparts, the cyclins (2, 3). The 
activation of Cdk2 by either cyclin E (CycE) or cyclin A (CycA) controls commitment to 
proliferation and initiation of DNA synthesis (4). However, Cdk2 activity can be opposed by 
p21 (Cip1/Waf1), a stoichiometric inhibitor that is under the control of the DNA damage-
induced transcription factor p53 (5, 6). Thus, p21 acts as a damage-dependent brake on cell 
cycle progression. p21 can also bind to proliferating cell nuclear antigen (PCNA), a vital 
component of the DNA replication machinery (7), where it competes with DNA processivity 
factors for PCNA binding and thus blocks DNA synthesis directly (8–10). These mechanisms 
enable p21 to maintain genome stability downstream of DNA damage by preventing the 
propagation of mutations to future cellular generations, which could otherwise lead to 
decreased cell fitness or tumorigenesis. This is consistent with observations that p21-/- 
mouse models show enhanced tumorigenesis (6, 11) and that p21 is required for the 
maintenance of haematopoietic and forebrain neural stem cells (12, 13). 
Using live single-cell imaging, Spencer and colleagues have shown that, following mitosis, 
proliferating cells bifurcate into one population that rapidly accumulates Cdk2 activity and re-
enters the cell cycle and another, quiescent population where Cdk2 activity is downregulated 
(14). This bifurcation is controlled by both mitogen stimulation and p21 expression (14, 15). 
Recently, we and others have observed that p21 protein levels show high cell-to-cell 
variability in genetically-identical, non-transformed cells due to intrinsic DNA damage 
suffered during unperturbed growth (16, 17). Frequently, this damage occurs during DNA 
replication causing p21 accumulation in the G2- and M-phases of a mother cell’s cycle. p21 is 
then inherited by daughter cells at cell division and determines their decision to proliferate. 
These results suggest that p21 is part of a control system that integrates information across 
generations to determine cell fate. In addition, the proliferation-quiescence decision appears 
to be reversible since DNA damage or extrinsic stress applied in G1 can revert cells back to a 
quiescent state (18). This window of reversibility is thought to be closed by the inactivation 
of the anaphase-promoting complex / cyclosome (APC/CCdh1), a ubiquitin ligase that targets 
many cell cycle regulators for degradation during G1, including CycA. 
Motivated by these experiments, we aimed to gain a systems-level understanding of the 
proliferation-quiescence decision and its response to endogenous, naturally occurring DNA 
damage. In a previous study, we developed and experimentally validated a mathematical 
model for p21 regulation, revealing a bistable switch at the G1/S transition that controls p21 
degradation (16). Here, we augment this model with the restriction point (RP), a second 
major cell cycle transition that gates cell cycle entry. We show that, by promoting p21 
synthesis, DNA damage can prevent passage through the RP and that, due to its bistable 
nature, the RP converts a graded p21 signal into an all-or-nothing cell cycle decision. Our 
model also suggests that DNA damage in post-RP G1 can reverse the decision to proliferate 
and reset cells to a pre-RP state. This window of reversibility ends at the G1/S transition 
when rapid p21 degradation prevents a response to DNA damage, which is vital to avoid 
premature S-phase exit. Finally, we show that G1 cells progressively lose the ability to revert 
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to quiescence as they approach the G1/S transition and that the loss of G1 regulators 
compromises the control system leading to different forms of dysregulated growth. Hence, 
our study demonstrates how cellular decision-making integrates information over time and 
how bistable switches can make cells both sensitive and tolerant to external stimuli. 
 
Results 
Developing a model for early cell cycle regulation 
To understand the control of cell cycle entry and subsequent progression, we built a 
mechanistic mathematical model of the underlying regulatory network (Fig. 1A). Our model 
links the two main transitions of early cell cycle regulation: the RP, where cells commit to 
proliferation, and the G1/S transition marking the onset of DNA replication (see SI Appendix 
for details). The G1/S module of the model is based on our previous work on p21 
dynamics (16) extended here by explicitly distinguishing between CycE and CycA. G1 
progression was modelled as follows: Passage through the RP requires growth factor-
dependent hyper-phosphorylation of the retinoblastoma protein (Rb), which alleviates 
inhibition of E2F transcription factors (19). Once active, E2Fs drive their own expression as 
well as the synthesis of CycE and CycA, both of which promote Cdk2 activity, further 
reinforcing Rb inhibition (20, 21). E2F-dependent transcription also causes expression of the 
early mitotic inhibitor (Emi1), an inhibitor of APC/CCdh1 (Cdh1), which is responsible for 
degradation of CycA during G1. Increasing levels of CycE:Cdk2 and CycA:Cdk2 then activate 
replication complexes (aRCs), initiating S-phase. DNA damage can halt this process by 
upregulating p53, which causes p21 expression, inhibiting both Cdk2 activity and DNA 
replication (5, 6). This is counteracted by two p21 degradation pathways depending on 
either Cdk2 or PCNA in aRCs (22).  
Deterministic simulations of this model show a distinct peak in CycE:Cdk2 levels, as well as 
an abrupt increase in CycA:Cdk2, at the G1/S transition (Fig. 1B), in good agreement with 
quantitative live-cell imaging data (23). Here, the accumulation of CycA is facilitated by the 
rapid inactivation of Cdh1 at S-phase entry, which is caused by both Emi1 expression and 
increased Cdk2 activity. We also observe the presence of p21 both before and after S-phase, 
while the inhibitor is absent during DNA replication, as has been shown experimentally (24). 
To capture the large cell-to-cell heterogeneity in p21 protein levels that has been reported, 
we performed stochastic simulations (Fig. 1C, top). We assumed that DNA damage occurs 
randomly throughout the cell cycle but is more likely to occur during S-phase, when 
chromosome replication takes place (25). The resulting simulations recapitulate both the 
spread and general pattern of experimental p21 levels (Fig. 1C and D) as well as the length 
of G1- and S-phase (Fig. 1E), suggesting that we can use the model to further analyse p21 
dynamics in the early cell cycle.  
Our model attributes the heterogeneity in p21 levels primarily to the stochasticity of DNA 
damage, i.e., the spontaneous occurrence and subsequent repair of DNA lesions. However, 
we also observe a dependence of p21 expression on the cell cycle stage (Fig. 1F and G). In 
particular, DNA damage in G1-phase causes an immediate increase in p21 (Fig. 1F), while S-
phase cells do not show such an increase and delay p21 accumulation until after the 
completion of DNA replication (Fig. 1G). As previously described, this is due to the presence 
of a bistable switch at the G1/S transition ((16) and SI Appendix, Fig. S1A, B). This switch 
promotes rapid p21 degradation during DNA replication (SI Appendix, Fig. S1C), while it 
allows p21 levels to vary in G1 and G2-phase. Thus, intrinsic DNA damage that occurs during 
S-phase results in elevated p21 protein levels in G2 and these elevated levels may persist for 
some time, even after the damage has been repaired (Fig. 1F). 
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Fig. 1 | A model of early cell cycle progression. (A) Influence diagram of the cell cycle model. 
Components associated with the RP and G1/S transition are shown separately for visual clarity, but 
are connected in the model. GF, growth factors; aRC, active replication complexes. (B) Deterministic 
simulation of the model in A. (C) p21 levels from stochastic simulations (top; n = 30) and experiments 
in individual hTert-RPE1 cells (bottom; n = 29). (D) Maximum p21 level in G1- and G2-phase in 
stochastic simulations (Sim; n = 200) and experiments (Exp; n = 186). Values were normalised to the 
median in G1-phase for each case. A two-sided Wilcoxon rank sum test shows no significant 
difference between experiment and simulation (G1: p = 0.65; G2: p = 0.33). (E) Comparison of G1- 
and S-phase lengths in stochastic simulations (Sim; n = 200) and experiments (Exp; n = 186). A two-
sided Wilcoxon rank sum test yields p = 0.78 (G1) and p = 0.64 (S). (F, G) Stochastic simulations of 
two cells that suffer DNA damage in different cell cycle phases. 
  
Inherited p21 promotes quiescence by blocking passage through the RP 
Having observed that DNA damage generated during DNA synthesis can lead to increased 
p21 expression only after S-phase exit, we wanted to understand how this affects cell cycle 
progression. Single-cell imaging data during unperturbed growth suggests that a moderate 
increase in p21 levels in G2- or M-phase does not impair progression through these 
stages (Fig. 2A). Instead, p21 protein is transferred from mother to daughter cells, where it 
can promote quiescence (16). Consistent with this, quiescent cells have been shown to 
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Fig. 2 | p21 impairs RP passage. (A) Experimental data of a cell that enters the cell cycle twice 
before becoming quiescent. (B) Subnetwork of the RP comprising two positive feedback loops (+). 
(C) Stable (solid) and unstable (dashed) steady states of E2F activity with respect to growth factor 
signalling. Diagram was calculated from the model in the absence of p21 using the subnetwork in B. 
(D) E2F activity in response to p21 at high growth factor levels based on the subnetwork in B. Arrows 
indicate the fate of cells on either side of the threshold. Total p21 levels were kept constant at the 
indicated level. (E) Stochastic simulations of two cells with different initial p21 levels using the full 
model in Fig. 1A. Marginal histograms depict initial p21 levels of additional simulations grouped into 
quiescent (grey) and proliferating (green) cells (n = 500). (F) Cdk2 activity from stochastic simulations 
of cells with different initial p21 levels as shown in E (n = 30). 
 contain high amounts of p21, as well as increased levels of hypo-phosphorylated Rb (14). 
The Rb protein is an essential component of a positive feedback system that creates the 
RP (Fig. 2B). An inherent property of positive feedback is its ability to create discontinuous 
switches (26) and a bistable Rb-E2F switch has been reported to underlie the RP (27). Our 
model supports this notion showing bistability in E2F activity in the absence of p21, with low 
concentrations of growth factors attracting cells to the quiescent state (Fig. 2C). Once a 
certain threshold of mitogens is reached, Rb is hyper-phosphorylated and E2F rapidly 
activated, facilitating progression through the RP. Note that this transition is irreversible in 
the absence of DNA damage such that cells become independent of growth factor 
stimulation once in the proliferating state, a hallmark of the RP (28).  
Extending on the previously known bistability of the RP, our model suggests that p21 can 
modulate the Rb-E2F switch such that cells can enter quiescence even under high growth 
factor stimulation if they contain increased p21 levels (Fig. 2D). This mechanism primarily 
depends on p21’s ability to inhibit Cdk2 activity and thereby prevent activation of the positive 
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feedback loops that are required to pass the RP (SI Appendix, Fig. S2A). Due to bistability, 
cells on either side of the p21 threshold exhibit very different fates. Whilst cells with sub-
threshold p21 levels continue to cycle, their supra-threshold counterparts enter quiescence 
(Fig. 2E). This dividing behaviour is even more apparent when considering Cdk2 
activity (Fig. 2F). Both populations show an initial decrease in Cdk2 activity at the end of 
mitosis as CycA is degraded by the APC/CCdc20. However, Cdk2 activity rapidly recovers in 
cells which contain low p21 levels, while high p21 levels prevent this recovery, in excellent 
agreement with live-cell imaging (14, 16). The stark contrast between both populations, and 
the fact the intermediate states are rarely observed, provide further evidence that bistability 
is indeed at the core of the proliferation-quiescence decision.  
In summary, our model suggests that p21 interferes with a bistable switch that controls RP 
passage to convert a graded p21 signal, which can be inherited from the mother cell (SI 
Appendix, Fig. S2B, C), into an all-or-nothing cell fate decision. It also shows that mitogen 
stimulation is necessary, but not sufficient, for proliferation. 
 
p21 degradation controls whether the proliferation decision can be reversed 
In addition to mitogen stimulation and past DNA damage that control whether a cell enters 
the cell cycle in the first place, it has been shown that the decision to proliferate can be 
reversed by exposure to stress and DNA damage in G1-phase (18). One mechanism that 
may mediate this response is an increased expression of p21 which inhibits cyclin:Cdk2 
activity and DNA synthesis (Fig. 3A). Indeed, our simulations show that DNA damage 
incurred during G1-phase can reverse Cdk2 activation, pushing cells back into a pre-RP state 
with low Cdk2 activity and unphosphorylated Rb (SI Appendix, Fig. S3A). However, whether 
the decision to proliferate is reversible depends on both the strength of DNA damage and its 
timing (Fig. 3B). Specifically, our model predicts that cells in early G1-phase are particularly 
susceptible to arrest, with low levels of DNA damage being sufficient to reset the cell cycle. 
As cells move towards S-phase they progressively lose this sensitivity such that more, or 
more sustained, DNA damage is required to revert to quiescence. Intriguingly, our 
simulations suggest that S-phase cells completely lose the ability to enter p21-induced 
quiescence in response to the low levels of intrinsic DNA damage we consider here. 
To test these model predictions, we introduced DNA damage into asynchronously cycling 
hTert-RPE1 cells with endogenously labelled mRuby-PCNA and p21-GFP, and followed their 
cell cycle fates and p21-GFP levels by time-lapse imaging. We imaged cells for 5 h to 
determine when they exited mitosis, before treating them with the DNA damage-inducing 
drug Camptothecin (CPT). We then tracked cells for a further 20 h to see whether they 
would enter S-phase or arrest. Control cells that were treated with DMSO almost exclusively 
entered S-phase, showing no bias for the length of time spent in G1 before 
treatment (Fig. 3C and SI Appendix, Fig. S3B). In sharp contrast, CPT-treated cells became 
increasingly less likely to enter quiescence the more time they had spent in G1. This is 
consistent with our model prediction that cells become less sensitive to DNA damage as they 
progress towards S-phase. Note that while we see an all-or-none response on the single-cell 
level, i.e., a cell either enters quiescence or fully commits to the cell cycle, experimental 
results compiled from multiple cells show a fractional response due to cell-to-cell variability. 
Our model specifically predicts that cells lose the ability to enter quiescence because of an 
increasing rate of p21 degradation. Two ubiquitin ligases can mediate p21 degradation: 
SCFSkp2 and CRL4Cdt2 (Fig. 3A, (22)). We recently showed that it is Skp2 that controls the 
turnover of p21 in G1 (16). Simulating our model in the absence of Skp2 suggests that this 
perturbation would cause cells to remain highly sensitive to DNA damage until late 
G1 (Fig. 3D). To test this prediction, we depleted Skp2 using siRNA and repeated the above 
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Fig. 3 | p21 degradation controls the ability to enter DNA damage-induced quiescence. 
(A) Subnetwork of DNA damage-induced control of early cell cycle progression including Skp2- and 
Cdt2-dependent p21 degradation pathways. (B) Effect of DNA damage of variable strength and timing 
on the decision to proliferate (bottom) in deterministic simulations of the full model in Fig. 1A. 
Damage was present from the indicated time until the end of the simulation. Time course of an 
undamaged cell is shown for comparison (top). (C, E, G) Experimental data showing the percentage 
of control-siRNA (C; n = 55, 77), Skp2-depleted (E; n = 71, 107) and Cdt2-depleted (G; n = 32, 52) 
cells that enter S-phase or arrest after treatment with DMSO or CPT at the indicated time post-
mitosis. (D, F) Same as in the lower panel of B for Skp2-depleted (D) and Cdt2-depleted (F) cells. 
 experiment. Consistent with our model, only those Skp2-depleted cells that were most 
advanced in G1 before CPT addition avoided quiescence (Fig. 3E). Furthermore, we find that 
while increasingly higher CPT doses are required to trigger quiescence in control cells as they 
advance in G1 (SI Appendix, Fig. S3C), Skp2 depletion leads to an abrupt, less drug dose-
dependent transition (SI Appendix, Fig. S3D), as suggested by our model.  
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Fig. 4 | Protein loss leads to deregulated proliferation. (A-D) Simulated effect of the presence 
of growth factors and DNA damage on the proliferation (blue)-quiescence (red) decision in 
unperturbed cells (A), and cells depleted for Rb (B), p21 (C) and Cdh1 (D). The indicated amount of 
damage and growth factors was present from the start of the simulation. 
 
 
A further model prediction is that cells become insensitive to p21-induced quiescence during 
S-phase because of strong Cdt2-mediated p21 degradation. More precisely, our simulations 
suggest that Cdt2 depletion would weaken the G1/S bistable switch (SI Appendix, Fig. S1D). 
This would allow p21 to re-accumulate during S-phase (SI Appendix, Fig. S3E), such that 
now even S-phase cells become susceptible to DNA damage-induced quiescence (Fig. 3F). 
Yet, susceptibility of Cdt2-depleted cells to quiescence in early and mid G1 would be 
unaffected. To test this, we depleted Cdt2 in hTert-RPE1 cells. Indeed, we observed that 
when these cells were treated with CPT in early and mid G1 they were still able to enter S-
phase (Fig. 3G). However, these cells only spend a short amount of time in S-phase and, 
more importantly, they re-accumulate p21 during DNA replication (SI Appendix, Fig. S3F, G), 
indicative of a reversion to quiescence. 
Taken together, these data confirm our model predictions that Skp2-dependent p21 
degradation leads to a progressive loss of sensitivity to DNA damage-induce quiescence in 
G1, which culminates in the Cdt2-mediated tolerance of DNA damage during S-phase. 
 
Loss of p21 and Rb causes uncontrolled proliferation 
The results above indicate that the Rb-p21 control network integrates signals from mitogen 
stimulation and DNA damage to mediate the proliferation-quiescence decision. Considering 
that many cancer cells have lost the ability to properly respond to these stimuli (29, 30), we 
used our model to explore which changes in the molecular network would compromise 
decision-making. With intact control, mitogen stimulation is necessary for proliferation such 
that cells below a certain threshold remain quiescent (Fig. 4A). Once this threshold is 
exceeded, the ratio between growth factor signalling and DNA damage, i.e., between the 
stimulation of Cdk2 activity by E2F-mediated cyclin synthesis and its inhibition by p21, 
controls proliferation. The molecular network integrates both stimuli and high amounts of 
damage or reduced mitogen levels will promote quiescence. Due to the presence of a 
bistable switch these continuous inputs are converted into a discontinuous, all-or-nothing cell 
fate decision, resulting in a sharp boundary between fates.  
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According to our model, a missing or non-functional Rb protein removes the necessity for 
mitogen stimulation with cells proliferating in the absence of growth factors (Fig. 4B), as has 
been found experimentally (31, 32). Yet, the system retains its ability to respond to DNA 
damage, albeit at much reduced sensitivity, i.e., the transition to a quiescent regime occurs 
at higher DNA damage levels. The latter is due to uninhibited E2F promoting substantial 
cyclin synthesis and Cdk2 activity, which requires a higher level of p21 induction to 
overcome. Loss of p21 protein has the opposite effect, abolishing DNA damage-induced 
quiescence, with the control by mitogens remaining in place (Fig. 4C). Finally, removal of 
Cdh1, another negative regulator of Cdk2 activity, makes cells less prone to enter quiescence 
in general. This is due to the increased accumulation of CycA:Cdk2 in G1-phase that provides 
another source of kinase activity that can promote RP passage (Fig. 4D). Yet, the Cdh1-
depleted system still responds to both mitogen stimulation and DNA damage.  
We decided to test the predictive value of our model by measuring the response of p21-
proficient versus p21-knockout (p21KO, (16)) cells to a range of concentrations of growth 
factors and DNA damage. Consistent with our model prediction, we find that p21KO cells 
proliferate much more readily (SI Appendix, Fig. S4). Quiescence is only triggered at very 
high drug doses, most likely by DNA damage-sensing signalling pathways that can cause cell 
cycle arrest under high levels of exogenous DNA damage, which we did not consider in the 
model presented here of the cellular response to relatively lower levels of endogenous DNA 
damage. 
In summary, our model suggests that the molecular network that controls the proliferation-
quiescence decision integrates growth factor signalling and DNA damage into an all-or-
nothing cell fate decision. Loss of Rb and p21 compromises the ability to enter quiescence in 
response to loss of mitogens and DNA damage, respectively, while Cdh1-depleted cells are 
more likely to proliferate in general.  
 
Discussion 
In this study, we developed a unifying model for the proliferation-quiescence decision in 
mammalian cells based on live single-cell imaging experiments. We show that two bistable 
switches underpin this decision: the RP, which mediates quiescence in response to serum 
starvation and DNA damage, and the G1/S transition allowing cells to tolerate intrinsic DNA 
damage during S-phase. The interplay between these switches establishes a window of 
reversibility, where cells otherwise committed to proliferation can revert to quiescence by 
expressing the Cdk inhibitor protein p21. 
The RP has long been recognised as a prototype example of a bistable commitment point in 
cell cycle progression, converting a graded mitogen signal into an all-or-none decision to 
proliferate (27). Our model suggests that p21 expression interferes with this switch by 
interrupting a positive Cdk2-Rb-E2F feedback loop. This establishes a p21 threshold for RP 
passage. Above this threshold, p21 prevents E2F activation by blocking Rb hyper-
phosphorylation, while at sub-threshold levels, Cdk2 can overcome p21 inhibition and 
phosphorylate Rb. Indeed, cells that exit mitosis with low p21 levels have been shown to 
maintain residual Cdk2 activity and Rb hyper-phosphorylation, which facilitates their re-entry 
into the cell cycle (14, 16). By contrast, intrinsic DNA damage incurred during S- or G2-
phases can increase p21 to supra-threshold levels, promoting quiescence in the subsequent 
cell cycle. We thus suggest that p21 connects the DNA damage response to the RP switch, 
where a continuous p21 signal is converted into an all-or-none cell cycle response (Fig. 5A). 
Spontaneous DNA damage during unperturbed growth can thus lead to a quiescent 
subpopulation of cells characterised by low Cdk2 activity and high p21 levels. However, this 
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Fig. 5 | Regulation of the proliferation-quiescence decision. The RP establishes a bistable 
switch with two distinct cell fates: quiescence and proliferation. (A) p21 carried over from the 
previous cycle can drive cells into quiescence by tipping the balance toward low Cdk2 activity, 
counteracting growth factor-mediated passage through the RP. (B) If initial p21 levels are low, growth 
factors can induce the re-accumulation of cyclin:Cdk2. Yet, DNA damage incurred during G1-phase 
may reverse the decision to proliferate by promoting p21 accumulation and Cdk2 inhibition. (C) In S-
phase, cells are insensitive to p21-induced quiescence as the Cdk inhibitor can no longer accumulate 
due to strong degradation. 
 
 
quiescent sub-population is absent in cell lines that have lost Rb or p53 function (23), as is 
the case in many cancers (29, 30).  
When first proposed, the RP was described as a transition that renders cell cycle progression 
independent of growth-factor stimulation (33, 34). In our model, the RP is indeed an 
irreversible switch that can maintain the proliferative state in the absence of mitogens. Yet, 
for the transition to occur in the first place a certain mitogen threshold has to be exceeded 
such that Rb can become hyper-phosphorylated and E2F activated. We show that this 
threshold is controlled by p21 levels. However, growth factors remain a necessary condition 
for cell cycle entry even in the complete absence of p21. Consistent with this, p21-knockout 
cells enter quiescence under serum starvation conditions (15, 16). Our model also suggests 
that once a critical serum level is reached, the decision to proliferate depends on the ratio of 
mitogen stimulation and DNA damage, in agreement with experimental results showing that 
competition between p21 and mitogen-regulated cyclin D1:Cdk4 controls cell cycle 
entry (35). The RP, hence, serves as a hub that integrates growth signals, which promote 
cyclin:Cdk2 activity, and DNA damage, which counteracts Cdk2 through p21 expression. In 
support of this, increasing serum concentrations drive more cells into the proliferating state, 
while DNA damage and high p21 levels cause quiescence (14–16).  
Previous studies have argued in favour of a singular decision point or window for cell cycle 
entry either located at the end of mitosis, in mid G1 or at the G1/S transition (14, 18, 33). 
Our simulations suggest that the interaction between the RP switch and the G1/S transition 
creates a decision window that extends at least throughout the entirety of G1 phase, where 
it integrates signals from mitogen-related pathways and DNA damage. During this window, 
cells that are committed to proliferation based on growth factor stimulation may revert to 
quiescence through DNA damage-induced p21 expression (Fig. 5B). Once cells do enter S-
phase, strong p21 degradation by Cdt2 prevents p21 re-expression, insulating S-phase from 
mild, intrinsic DNA damage (Fig. 5C). This provides a mechanistic explanation for recent data 
showing that, in contrast to G1 and G2, S-phase is comparatively insensitive to DNA 
damage (36). We speculate that this insensitivity is important to prevent cells from entering 
growth arrest with partly replicated DNA, from which they could later re-emerge starting a 
second round of replication. 
A recent study proposed that APC/CCdh1 inactivation constitutes a point of no return for cell 
cycle entry, preventing cells from entering quiescence in response to exogenous stress (18). 
However, Cdh1 inactivation temporally overlaps with the G1/S transition and thus with the 
onset of Cdt2-mediated p21 degradation. Moreover, by facilitating CycA:Cdk2 accumulation, 
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the inactivation of Cdh1 not only promotes the G1/S transition but also strengthens p21 
degradation via the Skp2-dependent pathway. Hence, Cdh1 regulation and p21 control are 
intimately linked. Nevertheless, our data suggest that it is p21 degradation that ultimately 
mediates the tolerance of intrinsic DNA damage. Two observations support this notion. First, 
compromising p21 degradation by Cdt2 depletion allows p21 re-accumulation during S-phase 
and premature S-phase exit despite Cdh1 control remaining in place. Second, Emi1-depleted 
cells that are treated with a Cdk inhibitor around the time of Cdh1 inactivation, i.e., at S-
phase entry, show an immediate re-activation of Cdh1 (18). Yet, when the same experiment 
is conducted in the absence of Cdk inhibition but presence of a DNA-damaging drug, Cdh1 
re-activation occurs only after a delay of several hours (18). We propose that, in this 
experiment, Cdh1 re-activation is caused by DNA damage-induced p21 inhibiting Cdk activity, 
and that the observed delay results from S-phase preventing p21 accumulation (SI Appendix, 
Fig. S3H, I). Thus, p21 degradation protects S-phase progression even when Cdh1 control is 
compromised. 
Taken together, we show that bistable transitions serve two different purposes during cell 
cycle entry. The RP switch integrates growth and damage signals, translating them into an 
all-or-none decision to proliferate, while the G1/S transition temporarily insulates cell cycle 
progression from the p21-mediated DNA damage response during S-phase. Hence, these 
ubiquitous control motifs can provide both sensitivity and robustness to external stimuli. 
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Methods 
Live cell imaging 
Both alleles of the endogenous CDKN1A locus were labelled at the C-terminus with GFP in 
hTert-RPE1 cells, generating a cell line where all p21 protein was labelled with GFP (16). In 
the same cells, a single allele of PCNA was labelled at the N-terminus with mRuby, in order 
to determine the timing of the G1/S transition, S-phase exit and mitosis (37). To follow p21-
GFP dynamics across the cell cycle, asynchronously cycling cultures growing in phenol-red 
free DMEM plus 10% FBS, were imaged every 10 mins on the Opera HCS microscope, using 
a 20x objective (NA 0.45) for up to 72 hrs. Automated image analysis was used to extract 
p21-GFP levels over time, relative to cell cycle transitions (38). 
In order to test the sensitivity of G1 cells to DNA damage, cells were reverse-transfected 
with either control, Skp2- or Cdt2-targeting siRNAs (Dharmacon ONTargetPlus siRNA pools) 
24 hrs before time-lapse imaging, using Lipofectamine RNAiMax (Invitrogen), according to 
the manufacturer’s instructions. Efficient depletion of Skp2 and Cdt2 protein levels by these 
siRNAs has been previously evaluated in this cell line (see (16)). Cells were filmed for 5 
hours prior to the addition of Camptothecin (CPT) or DMSO and filming was continued for 20 
hrs post-drug addition. mRuby-PCNA expression in these cells was used to determine the 
time of mitotic exit and the time of S-phase entry. A cell was classified as quiescent if it 
spend more than 600 min in G1, which we previously showed is consistent with a lack of 
both Rb hyper-phosphorylation and Cdk2 activity (16). 
 
Analysis of proliferation-quiescence decisions in response to p21 knockout 
hTert-RPE1 mRuby-PCNA p21-wild-type or hTert-RPE1 mRuby-PCNA p21KO cells (16) were 
plated in a 384-well CellCarrier plate at a density of 2000 cells/well in DMEM with 10% FBS. 
Once cells had attached, cells were washed three times in PBS and replaced with DMEM 
containing no FBS. Cells were serum-starved in this way for 72 hrs. We then added a range 
of concentrations of FBS and CPT in DMEM to cells and incubated for a further 24 hrs before 
fixing in 4% paraformaldehyde. Cells were permeabilised in PBS/0.2% TritonX-100, blocked 
in 2% BSA/PBS and immunostained with phospho-807/811 Rb antibody (CST 9308), in order 
to differentiate between quiescent and proliferating cells. Phospho-Rb antibody was detected 
by goat anti-rabbit Alexa 647 secondary antibody (ThermoFisher) and Hoescht was used to 
label nuclei. Plates were imaged on an Opera HCS (PerkinElmer) using a 20x objective, NA 
0.45. Automated image analysis was performed using Columbus to determine the 
percentage of quiescent cells per condition. Briefly, nuclei were segmented using the 
Hoescht stain and mitotic, dead and poorly segmented cells were excluded, using intensity 
and morphology thresholds. The phospho-Rb intensity was quantified for each nucleus, and 
by calculating a threshold for proliferating cells, we could extract the percentage of quiescent 
cells per condition.  
 
Mathematical modelling 
Our model of cell cycle progression (see Fig. 1A), comprises a set of ordinary differential 
equations (see SI Appendix for details), which provide the basis for deterministic and 
stochastic simulations shown in the main text. A deterministic version of the model was 
prepared using the Systems Biology Toolbox 2 (39) for MatLab (version 9.1.0 R2016b) and 
simulated with the CVODE routine (40). Bifurcation diagrams were calculated using the freely 
available software XPP-Aut (41). We simulated a stochastic version of the model using 
custom-made MatLab code of the stochastic simulation algorithm, also known as Gillespie’s 
14 
 
algorithm (reviewed in (42)), according to the sorting direct method (43). The model is 
provided as Dataset S1 and different versions of it are available at 
www.cellcycle.org.uk/publication. The model has also been deposited in BioModels (44) and 
assigned the identifier MODEL1703030000. 
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Supporting figures 
 
 
 
Fig. S1. A bistable switch controls p21 levels (related to Fig. 1). (A) Subnetwork of p21 regulation 
comprising three mutual inhibition motifs that involve Skp2- and Cdt2-dependent degradation 
pathways. (B) Stable (solid) and unstable (dashed) steady states of p21 during S-phase entry (left) 
and exit (right), calculated from the model using the subnetwork in A. Each line represents a different 
level of constant DNA damage. The G1/S transition is indicated for intermediate damage levels. Note 
the difference in y-axis scales. (C) Dynamics of cell cycle regulators (top), Skp2-dependent p21 
degradation (middle) and Cdt2-dependent p21 degradation (bottom) in deterministic simulations. p21 
degradation via Skp2 is linked to CycE- and CycA-associated Cdk2 activity, while Cdt2-dependent 
degradation depends on active replication complexes (aRC). Note the differences in y-axis scales 
between middle and bottom panels. (D) G1/S transition for low levels of DNA damage in a control 
simulation (unperturbed) and in the absence of Skp2 (-Skp2) and Cdt2 (-Cdt2). Note that the -Cdt2 
curve overlaps with the control simulation for low cyclin:Cdk2 levels. 
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Fig. S2. p21 impairs RP passage (related to Fig. 2). (A) Same as in Fig. 2C except that total p21 was 
set to the indicated level. (B) Deterministic simulations of cells suffering increasing amounts of DNA 
damage (bottom to top) during S-phase. (C) Final p21 level of cells shown in (B) over the strength of 
DNA damage. Dashed line indicates the p21 level that would cause quiescence in daughter cells 
assuming that p21 protein is inherited but the damage repaired. 
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Fig. S3. p21 degradation controls reversibility of proliferation decision (related to Fig. 3). 
(A) Deterministic simulation of a cell that suffers DNA damage during G1-phase and enters quiescence 
(solid) using the full model in Fig. 1A. An undamaged cell is shown for comparison (dashed). 
(B) Percentage of unperturbed cells that enter S-phase or arrest after treatment with DMSO or CPT at 
the indicated time post-mitosis (n = 45, 59). Note that cells in this experiment were only imaged for 
4 h prior to drug addition. (C, D) Percentage of control siRNA-treated (B; n = 292) and Skp2-
depleted (C; n = 279) cells that enter S-phase (red to blue) in experiments after treatment with the 
indicated amount of CPT at the indicated time post-mitosis. Note that Fig. 3 and S3B show a different 
set of experiments, which were conducted at a single concentration of 1.25 μM CPT. (E) p21 levels 
from stochastic simulations of Cdt2-depleted cells in the absence of extrinsic DNA damage (n = 30). 
(F, G) Experimental p21 levels in control-siRNA (F; n = 10) and Cdt2-depleted (G; n = 10) hTert-RPE1 
cells that entered S-phase after being treated with CPT at the times indicated by black dots. (H, 
I) Deterministic simulations of an unperturbed (H) and an Emi1-depleted (I) cell that suffer damage 
after S-phase entry. Note the re-activation of Cdh1 in G2-phase in response to DNA damage in the 
absence of Emi1. 
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Fig. S4. Loss of p21 leads to deregulated proliferation (related to Fig. 4). (A, B) Percentage of wild-
type (A; n = 41224) and p21-knockout (B; n = 133004) cells that enter S-phase (red to blue) in 
experiments after treatment with the indicated amount of CPT and growth factors (FBS) that were 
present from the beginning until the end of the experiment. Cells were serum-starved for 72 h before 
the experiment. 
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Mathematical modelling 
Restriction point 
Entry into the cell cycle is control by the restriction point. In order to pass through it, cells 
hyper-phosphorylate the Rb protein (𝑅𝑏), an inhibitor of the transcription factor E2F (19). 
d(𝑅𝑏u)
d𝑡
= −𝑟Rb
Ph ∙ 𝑅𝑏𝑢 + 𝑘Rb
Dp
∙ 𝑅𝑏p, ( 1 ) 
with 𝑟Rb
Ph = 𝑘Rb,Cd
Ph ∙ 𝐶𝑑 + 𝑘Rb,Ce
Ph ∙ 𝐶𝑒 + 𝑘Rb,Ca
Ph ∙ 𝐶𝑎,  
and 𝑅𝑏t = 𝑅𝑏u + 𝑅𝑏p = 𝑅𝑏 + 𝑅𝑏𝐸2𝐹 + 𝑅𝑏p,  
where 𝑅𝑏t, 𝑅𝑏p, and 𝑅𝑏u denote total, hyper- and hypo-phosphorylated Rb, respectively. The 
latter comprises both free Rb (𝑅𝑏) and Rb:E2F complexes (𝑅𝑏𝐸2𝐹). In our model, 
phosphorylation occurs with rate 𝑟Rb
Ph and is mediate by three cyclin:Cdk complexes: 
CycD:Cdk4/6 (𝐶𝑑), CycE:Cdk2 (𝐶𝑒) and CycA:Cdk2 (𝐶𝑎) with their specific phosphorylation 
rates 𝑘Rb,Cd
Ph , 𝑘Rb,Ce
Ph  and 𝑘Rb,Ca
Ph , respectively (4). The dephosphorylation rate is 𝑘Rb
Dp
. In its 
hypo-phosphorylated state Rb binds free E2F (𝐸2𝐹) impairing its ability to promote 
transcription (19). Hence, we assumed that Rb (hyper-)phosphorylation prevents E2F binding 
and leads to the dissociation of Rb:E2F complexes. 
d(𝐸2𝐹t)
d𝑡
= 𝑟E2F
Sy
− 𝑘E2F
De ∙ 𝐸2𝐹t, ( 2 ) 
d(𝐸2𝐹)
d𝑡
= 𝑟E2F
Sy
− 𝑘E2F
De ∙ 𝐸2𝐹 − 𝑘RbE2F
As ∙ 𝑅𝑏 ∙ 𝐸2𝐹 + (𝑘RbE2F
Ds + 𝑟Rb
Ph) ∙ 𝑅𝑏𝐸2𝐹, ( 3 ) 
with 𝑟E2F
Sy
= 𝑘E2F
Sy
+ 𝑘E2F,E2F
𝑆𝑦 𝐸2𝐹
𝑗E2F
Sy
+𝐸2𝐹
,  
and 𝐸2𝐹𝑡 = 𝐸2𝐹 + 𝑅𝑏𝐸2𝐹.  
Here, 𝐸2𝐹t and 𝐸2𝐹 are total and free E2F, respectively, and 𝑟E2F
Sy
 and 𝑘E2F
De  denote the E2F 
synthesis and degradation rate, respectively. Note that E2F promotes its own 
transcription (20). Hence, we assumed that synthesis occurs with a constitutive rate (𝑘E2F
Sy
) 
and an E2F-dependent rate (𝑘E2F,E2F
Sy
), where half-maximal synthesis is reach at 𝑗E2F
Sy
. 
Association and dissociation of Rb and E2F are described by the rates 𝑘RbE2F
As  and 𝑘RbE2F
Ds , 
respectively. 
 
Synthesis and degradation of cyclins and Emi1 
Activation of E2F drives the synthesis of a battery of genes that are essential for early cell 
cycle progression (4, 20). Among these are Emi1 (𝐸1), CycE (𝐶𝑒) and CycA (𝐶𝑎). 
d(𝐸1t)
d𝑡
= 𝑘E1
Sy
∙ 𝐸2𝐹 − 𝑘E1,C1
De ∙ 𝐸1𝐶1 − 𝑘E1
De ∙ 𝐸1, ( 4 ) 
d(𝐶𝑒t)
d𝑡
= 𝑘Ce
Sy
∙ 𝐸2𝐹 − 𝑟Ce
De ∙ 𝐶𝑒t, ( 5 ) 
d(𝐶𝑎t)
d𝑡
= 𝑘Ca
Sy
∙ 𝐸2𝐹 − 𝑟Ca
De ∙ 𝐶𝑎t, ( 6 ) 
with 𝑟Ce
De = 𝑘Ce
De + 𝑘Ce,Ca
De ∙ 𝐶𝑎,  
𝑟Ca
De = 𝑘Ca
De + 𝑘Ca,C1
De ∙ 𝐶1,  
and 𝐸1t = 𝐸1 + 𝐸1𝐶1,  
where the index t denotes total protein levels including all complexes that contain the 
protein. 𝐶1 and 𝐸1𝐶1 correspond to APC/CCdh1 and its complex with Emi1, respectively (see 
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below). The synthesis rates of Emi1, CycE and CycA are 𝑘E1
Sy
, 𝑘Ce
Sy
 and 𝑘Ca
Sy
, respectively, while 
degradation occurs with the constitutive rates 𝑘E1
De, 𝑘Ce
De and 𝑘Ca
De. In addition, Emi1 in 
Emi1:APC/CCdh1 complexes and CycA are degraded with the APC/CCdh1-depenent rates 𝑘E1,C1
De  
and 𝑘Ca,C1
De , respectively (45), while CycE is degraded with the CycA-dependent rate 
𝑘Ce,Ca
De  (46, 47). Note that since Cdk2 is in excess over its cyclins (48), 𝐶𝑒 and 𝐶𝑎 as well as 
their related variables correspond directly to the levels of CyclE:Cdk2 and CyclA:Cdk2 
complexes, respectively. 
 
Inactivation of APC/CCdh1 
APC/CCdh1 is an ubiquitin E3 ligase that is active from late mitosis to late G1-phase and 
targets key cell cycle regulators for degradation (45, 49). Its inhibition by Emi1 and by 
cyclin:Cdk2-mediated phosphorylation is crucial for G1/S progression (23, 45). Therefore, we 
assumed that APC/CCdh1 can exists in a free, active form (𝐶1) as well as two inactive forms: 
as part of an Emi1:APC/CCdh1 complex (𝐸1𝐶1) and as a free but Cdk2-phosphorylated 
form (𝐶1𝑝). 
d(𝐶1)
d𝑡
− 𝑟C1
Ph ∙ 𝐶1 + 𝑘C1
Dp
∙ 𝐶1p − 𝑘E1C1
As ∙ 𝐸1 ∙ 𝐶1 + (𝑘E1C1
Ds + kE1,C1
De ) ∙ E1C1, ( 7 ) 
d(𝐸1𝐶1)
d𝑡
= −𝑟C1
Ph ∙ 𝐸1𝐶1 + 𝑘E1C1
As ∙ 𝐸1 ∙ 𝐶1 − (𝑘E1C1
Ds + kE1,C1
De ) ∙ 𝐸1𝐶1, ( 8 ) 
with 𝑟C1
Ph = 𝑘C1
Ph + 𝑘C1,Ce
Ph ∙ 𝐶𝑒 + 𝑘C1,Ca
Ph ∙ 𝐶𝑎,  
and 𝐶1𝑡 = 𝐶1 + 𝐶1𝑝 + 𝐸1𝐶1.  
Here, phosphorylation occurs with rate 𝑟C1
Ph comprising the constitutive rate 𝑘C1
Ph as well as 
the cyclin:Cdk2-dependent rates 𝑘C1,Ce
Ph  and 𝑘C1,Ca
Ph . We assumed that Emi1:APC/CCdh1 
complexes dissociate upon phosphorylation. Dephosphorylation is described by 𝑘C1
Dp
. The 
rates of association and dissociation of APC/CCdh1 and Emi1 are 𝑘E1C1
As  and 𝑘E1C1
Ds , respectively. 
Note that Emi1 is assumed to act as a pseudo-substrate for the APC/C (50). Hence, we 
chose 𝑘E1,C1
De > 𝑘E1
De (see Eq. ( 4 )). 
 
p21 dynamics and Cdk2 inhibition 
Activation of Cdk2 drives G1/S progression but its kinase activity is opposed by the 
stoichiometric inhibitor p21 (51). Hence, our model accounts for free p21 (𝑃21) and its 
ability to bind active CycE:Cdk2 (𝐶𝑒) and CycA:Cdk2 (𝐶𝑎) complexes. The resulting 
complexes of CycE:Cdk2:p21 (𝐶𝑒𝑃21) and CycA:Cdk2:p21 (𝐶𝑎𝑃21) are considered inactive. 
d(𝑃21t)
d𝑡
= 𝑘P21
Sy
+ 𝑘P21,P53
Sy
∙ 𝑃53 − 𝑟P21
De ∙ 𝑃21t, ( 9 ) 
d(𝐶𝑒𝑃21)
d𝑡
= 𝑘CyP21
As ∙ 𝑃21 ∙ 𝐶𝑒 − (𝑘CyP21
Ds + 𝑟Ce
De + 𝑟P21
De ) ∙ 𝐶𝑒𝑃21, ( 10 ) 
d(𝐶𝑎𝑃21)
d𝑡
= 𝑘CyP21
As ∙ 𝑃21 ∙ 𝐶𝑎 − (𝑘CyP21
Ds + 𝑟Ca
De + 𝑟P21
De ) ∙ 𝐶𝑎𝑃21, ( 11 ) 
with 𝑟P21
De = 𝑘P21
De + 𝑘P21,Cy
De ∙ 𝑆𝑘𝑝2 ∙ (𝐶𝑒 + 𝐶𝑎) + 𝑘P21,RCa
De ∙ 𝐶𝑑𝑡2 ∙ 𝑅𝑐a  
𝑃21t = 𝑃21 + 𝐶𝑒𝑃21 + 𝐶𝑎𝑃21 + 𝑃𝑐𝑛𝑎i + 𝑅𝑐i,  
𝐶𝑒𝑡 = 𝐶𝑒 + 𝐶𝑒𝑃21,  
𝐶𝑎𝑡 = 𝐶𝑎 + 𝐶𝑎𝑃21.  
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Here, synthesis of p21 occurs with the constitutive rate 𝑘P21
Sy
 and the p53-dependent rate 
𝑘P21,P53
Sy
, where 𝑃53 denots the transcription factor p53 (5). The degradation rate of p21 is 
denoted 𝑟P21
De  and comprises a constitutive rate (𝑘P21
De ) as well as a cyclin:Cdk2-dependent 
rate (𝑘P21,Cy
De ) that is linked to the ubiquitin E3 ligase SCFSkp2 (𝑆𝑘𝑝2, (22, 52)). In addition, 
CRL4Cdt2 (𝐶𝑑𝑡2), which is recruited to chromatin-bound PCNA within active replication 
complexes (𝑅𝑐a, see below), can mediate p21 degradation with rate 𝑘P21,RCa
De  (22, 53). In our 
model, free p21 can bind to cyclin:Cdk2 complexes with rate 𝑘CyP21
As  and dissociate from 
these complexes with rate 𝑘CyP21
Ds . Furthermore, the total amount of p21 (𝑃21t) comprises 
free p21 (𝑃21) as well as p21 in complexes with cyclin:Cdk2 (𝐶𝑒𝑃21 and 𝐶𝑎𝑃21), 
PCNA (𝑃𝑐𝑛𝑎i), and replication complexes (𝑅𝑐i, see below). 
 
Activation of DNA replication 
During S-phase, DNA is synthesised by specialised replication complexes that assemble on 
licensed replication origins once there is sufficient Cdk2 activity (54). Therefore, we assumed 
that Cdk2 activates pre-replication complexes (𝑅𝑐) such that they are primed (𝑅𝑐p) for the 
loading of DNA processivity factors. 
d(𝑅𝑐)
d𝑡
= −𝑟Rc
Ph ∙ 𝑅𝑐 + 𝑘Rc
Dp
∙ 𝑅𝑐p − 𝑟Rc
Ds ∙ 𝑅𝑐, ( 12 ) 
with 𝑟Rc
Ph = 𝑘Rc
Ph (𝐶𝑒+𝐶𝑎)
𝑛
(𝑗Cy)
𝑛
+(𝐶𝑒+𝐶𝑎)𝑛
,  
where priming occurs with rate kRc
Ph in an ultrasensitive fashion with hill coefficient n at a 
cyclin:Cdk2 threshold of 𝑗Cy. Primed replication complexes can revert back to an unprimed 
state with a small rate 𝑘Rc
Dp
 and replication complexes are disassembled upon completion of 
S-phase with rate 𝑟Rc
Ds (see below). Once primed, replication complexes can bind 
PCNA, which forms a trimeric complex around the DNA that serves as a sliding platform for 
other processivity factors (7). We assumed that either free PCNA (𝑃𝑐𝑛𝑎a) or PCNA:p21 
complexes (𝑃𝑐𝑛𝑎i) are bound leading to the formation of active (𝑅𝑐a) or inactive (𝑅𝑐i) 
replication complexes, respectively. 
d(𝑅𝑐p)
d𝑡
= 𝑟Rc
Ph ∙ 𝑅𝑐 − 𝑘Rc
Dp
∙ 𝑅𝑐p − 𝑘RcPc
As ∙ (𝑃𝑐𝑛𝑎a + 𝑃𝑐𝑛𝑎i) ∙ 𝑅cp + 𝑘RcPc
Ds ∙ (𝑅𝑐a + 𝑅𝑐i)
− 𝑟Rc
Ds ∙ 𝑅𝑐p, 
( 13 ) 
d(𝑅𝑐a)
d𝑡
= −𝑘PcP21
As ∙ 𝑃21 ∙ 𝑅𝑐a + (𝑘PcP21
Ds + 𝑟P21
De ) ∙ 𝑅𝑐i + 𝑘RcPc
As ∙ 𝑃𝑐𝑛𝑎a ∙ 𝑅cp − 𝑘RcPc
Ds ∙ 𝑅𝑐a
− 𝑟Rc
Ds ∙ 𝑅𝑐a, 
( 14 ) 
d(𝑅𝑐i)
d𝑡
= 𝑘PcP21
As ∙ 𝑃21 ∙ 𝑅𝑐a − (𝑘PcP21
Ds + 𝑟P21
De ) ∙ 𝑅𝑐i + 𝑘RcPc
As ∙ 𝑃𝑐𝑛𝑎i ∙ 𝑅cp − 𝑘RcPc
Ds ∙ 𝑅𝑐i
− 𝑟Rc
Ds ∙ 𝑅𝑐i. 
( 15 ) 
The rates of PCNA loading and unloading are 𝑘RcPc
As  and 𝑘RcPc
Ds , respectively. Also note that 
p21 is the strongest known binding partner of PCNA (9) and it was proposed to compete 
with other PCNA-binding proteins (7, 8). Thus, we assumed that binding of p21 to active 
replication complexes with rate 𝑘PcP21
As  (or binding of PCNA:p21 to primed replication 
complexes) creates inactive replication complexes (10, 55). The dissociation of p21 from 
PCNA occurs with rate 𝑘PcP21
Ds . In our model, active replication complexes synthesise 
DNA (𝐷𝑁𝐴) and once DNA replication is finished, replication complexes disassemble with 
rate 𝑟Rc
Ds. 
d(𝐷𝑁𝐴)
d𝑡
= 𝑘DNA
Sy
∙ 𝑅𝑐a, ( 16 ) 
and 𝑟Rc
Ds = 𝐻(𝐷𝑁𝐴 − 1),  
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where 𝑘DNA
Sy
 is the DNA synthesis rate and 𝐻 the Heaviside function. 
 
PCNA dynamics 
We assumed that free PCNA in the nucleus (𝑃𝑐𝑛𝑎a) is replenished from a cytoplasmic pool 
and that p21 can bind to PCNA creating PCNA:p21 complexes (𝑃𝑐𝑛𝑎i, (9)). 
d(𝑃𝑐𝑛𝑎a)
d𝑡
= 𝑘Pc
Im − 𝑘PcP21
As ∙ 𝑃21 ∙ 𝑃𝑐𝑛𝑎a + (𝑘PcP21
Ds + 𝑟P21
De ) ∙ 𝑃𝑐𝑛𝑎i 
              −(𝑘Pc
Ex + 𝑘RcPc
As ∙ 𝑅𝑐p) ∙ 𝑃𝑐𝑛𝑎a + (𝑘RcPc
Ds + 𝑟Rc
Ds) ∙ 𝑅𝑐a, 
( 17 ) 
d(𝑃𝑐𝑛𝑎i)
d𝑡
= 𝑘PcP21
As ∙ 𝑃21 ∙ 𝑃𝑐𝑛𝑎a − (𝑘PcP21
Ds + 𝑟P21
De ) ∙ 𝑃𝑐𝑛𝑎i 
              −(𝑘Pc
Ex + 𝑘RcPc
As ∙ 𝑅𝑐p) ∙ 𝑃𝑐𝑛𝑎i + (𝑘RcPc
Ds + 𝑟Rc
Ds) ∙ 𝑅𝑐i. 
( 18 ) 
Here, 𝑘Pc
Im and 𝑘Pc
Ex denote the nuclear import and export rate PCNA, respectively. The 
association and dissociation of p21 and PCNA occur with rate 𝑘PcP21
As  and 𝑘PcP21
Ds , respectively. 
The binding and unbinding rates of PCNA and replication complexes are 𝑘RcPc
As  and 𝑘RcPc
Ds , 
respectively. 
  
DNA damage and repair 
In our model, DNA damage (𝐷𝑎𝑚) can either occur independent of the cell cycle stage or 
specifically during DNA replication. It induces the expression of p53 (𝑃53), which promotes 
damage repair processes (56). 
d(𝐷𝑎𝑚)
d𝑡
= 𝑘Dam
Ge + 𝑘Dam,RCa
Ge ∙ 𝑅𝑐a − 𝑟Dam
Re ∙ 𝐷𝑎𝑚, ( 19 ) 
d(𝑃53)
d𝑡
= 𝑘P53
Sy
− 𝑟P53
De ∙ 𝑃53, ( 20 ) 
with 𝑟Dam
Re = 𝑘Dam
Re + 𝑘Dam,P53
Re 𝑃53
𝑗𝐷𝑎𝑚+𝐷𝑎𝑚
,  
and 𝑟P53
De =
𝑘𝑃53
De
𝑗P53+𝐷𝑎𝑚
,  
where 𝑘Dam
Ge  and 𝑘Dam,RCa
Ge  correspond to the constitutive and DNA replication-dependent 
rates of damage induction, respectively. Damage is repaired with a constitutive rate (𝑘Dam
Re ) 
and a p53-dependent rate (𝑘Dam,P53
Re ) assuming that p53 expression triggers repair processes. 
The latter reaches its half-maximal rate at a damage level of 𝑗𝐷𝑎𝑚. Since DNA damage has 
been shown to stabilize p53 (57), we assumed that p53 synthesis occurs with a constitutive 
rate (𝑘P53
Sy
), while degradation occurs with rate 𝑘𝑃53
De , which is inversely proportional to the 
sum of DNA damage and an inhibition constant 𝑗P53. 
 
Cdh1 activity reporter 
In order to compare our simulation results with measurements of Cdh1 activity obtained by 
following the degradation of a model APC/CCdh1 substrate (18), we simulated such an activity 
probe (𝑃𝑟). 
d(𝑃𝑟)
d𝑡
= 𝑘Pr
Sy
− (𝑘Pr
De + 𝑘Ca,C1
De ∙ 𝐶1) ∙ 𝑃𝑟, ( 21 ) 
where the constitutive synthesis and degradation rates of the probe are 𝑘Pr
Sy
 and 𝑘Pr
De, 
respectively, and, without loss of generality, the Cdh1-dependent degradation rate 𝑘Ca,C1
De  is 
the same than for CycA. Based on the analysis of experimental data (18), we calculated 
Cdh1 activity (𝐶1act) using the following equation. 
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𝐶1act =  
𝑘Pr
Sy
−
Δ(𝑃𝑟 + 𝐵𝑔)
Δ𝑡
𝑃𝑟 + 𝐵𝑔
. ( 22 ) 
Here, we added a small background signal (𝐵𝑔) to reflect that while small changes in probe 
concentration can be accurately calculated from numerical data they might be below the 
signal-to-noise ratio in experiments. 
 
Computation 
A deterministic version of the model was prepared using the Systems Biology Toolbox 2 (39) 
for MatLab (version 9.1.0 R2016b) and simulated with the CVODE routine (40). Bifurcation 
diagrams were calculated using the freely available software XPP-Aut (41). The model is 
provided as Dataset S1 and different versions of it are available at 
www.cellcycle.org.uk/publication. The model was also deposited in BioModels (44) and 
assigned the identifier MODEL1703030000. 
We simulated a stochastic version of the model using custom-made MatLab code of the 
stochastic simulation algorithm, also known as Gillespie’s algorithm (reviewed in (42)), 
according to the sorting direct method (43). To this end, the rate expressions of the 
deterministic model were converted into propensity functions, which requires the 
transformation of the relative levels of cell cycle regulators into numbers of molecules. Here, 
we followed the system in a control volume containing on average 1000 molecules/AU of 
protein and 1 event/AU of DNA damage. Hence, most of the simulated cell-to-cell variability 
originates in the stochastic infliction of DNA damage, while transcriptional and translational 
noise play only a minor role. To account for the extrinsic noise observed in our experiments, 
i.e., the variability in p21 levels after cell division, we chose the initial p21 level for each 
cell (simulation run) from a log-normal distribution with μ = -0.5 and σ = 0.3. This 
distribution is based on the distribution of initial p21 levels estimated from experiments 
(μ = 2.4, σ = 0.3), which was rescaled to account for the difference in p21 level between 
experiments and simulations. For the simulation of depletion experiments 𝑆𝑘𝑝2 and/or 𝐶𝑑𝑡2 
were reduced to 1%. 
To classify cells as either proliferating or quiescent we used the fact that these two fates 
represent attractors in state space in our model (see Fig. 2C-F). In particular, quiescent cells 
are characterised by high p21 levels as well as low Cdk2 activity, Rb hypo-phosphorylation 
and low E2F activity, which prevents entry into S-phase. Hence, simulated cells that maintain 
these features were classified as quiescent, while cells that did enter S-phase were deemed 
proliferating. 
 
Model parameters 
Parameter values and non-zero initial conditions of the model are listed in Tables S1 and S2, 
respectively. A large part of the parameter set is based on our previously published study of 
p21 dynamics (16), where the model was parameterised to capture p21 dynamics in 
individual, unperturbed hTert-RPE1 cells as well as in perturbation experiments such as upon 
depletion of Skp2 and Cdt2. This includes parameters for p21 synthesis and degradation, the 
import, export, phosphorylation and binding of PCNA, and the dynamics of p53 and DNA 
damage. Parameter values for the newly added restriction point module are based on 
experimental observations and were adapted to reproduce cell cycle progression in RPE1 
cells (see Fig. 1C-E). In particular, we assumed that in its hypo-phosphorylated state Rb 
binds tightly to E2F as it was shown to act as a stoichiometric inhibitor (19). Synthesis and 
degradation of E2F were chosen to yield a bistable response, which was found 
experimentally (27). Inhibition of APC/CCdh1 by Emi1 was modelled via a pseudo-substrate 
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inhibitor mechanism (50), implying tight binding of both and a slow turnover of Emi1 by 
Cdh1. Synthesis and degradation of Emi1 and phosphorylation of APC/CCdh1 were adjusted to 
yield a rapid, switch-like inactivation of APC/CCdh1 at the G1/S transition based on 
measurements of APC/C activity (18). Parameters for CycE and CycA synthesis and 
degradation were chosen to qualitatively match the measurements of both proteins in live, 
single cells (23) and of overall Cdk2 activity (14, 16), while accounting for the length of cell 
cycle phases in RPE1 cells (see Fig. 1E). Local parameter sensitivities (see Table S1) were 
calculated according to 
𝑆𝜃 =
Δ𝑀
𝑀
𝜃
Δ𝜃
 with 
Δ𝑀
𝑀
=
1
𝑁𝑉𝑁𝑡
∑ (
𝑦𝑉(𝜃, 𝑡) − 𝑦𝑉(𝜃
∗, 𝑡)
𝜎𝑉
)
2
𝑉,𝑡
 
where 𝑆𝜃 is the local sensitivity of parameter 𝜃, comprising the relative change in model 
output 𝑀 with respect to the relative change in parameter 𝜃. The relative change in model 
output was defined as the squared change in state variable 𝑉 at time 𝑡 given the original 
parameter set (𝑦𝑉(𝜃, 𝑡)) and the same output in response to a parameter change (𝑦𝑉(𝜃
∗, 𝑡)), 
normalised by the maximum value of variable 𝑉 (𝜎𝑉), which was summed over all time 
points and state variables and normalised to the number of simulated time points (𝑁𝑡) and 
state variables (𝑁𝑉), following (58). 
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Supporting tables 
Table S1. Parameters of the mathematical model. 
Parameter Description Value Unit 
Local 
Sensitivity 
(%) 
𝐵𝑔 background of Cdh1-activity probe 0.05 AU  
𝐶1t total APC/CCdh1 level 1 AU 0.26 
𝐶𝑑 relative CycD:Cdk4/6 level 0.65 AU 1.33 
𝐶𝑑𝑡2 relative CRL4Cdt2 level 1 (0.01a)  0.01 
𝑅𝑏t total Rb level 5 AU 4.42 
𝑆𝑘𝑝2 relative SCFSkp2 level 1 (0.01a)  0.14 
𝑗Cy Cdk2 threshold for RC priming 1.8 AU 2.4 
𝑗Dam DNA damage threshold for repair 0.5 AU 0.002 
𝑗P53 inhibition constant of p53 degradation 0.01 AU 1∙10
-4 
𝑗E2F
Sy
 Michealis-Menten constant for E2F synthesis 0.2 AU 0.7 
𝑘CyP21
As  association of p21 and cyclin:Cdk2 1 1/(AU∙min) 0.002 
𝑘E1C1
As  association of Emi1 and APC/CCdh1 10 1/(AU∙min) 0.1 
𝑘PcP21
As  association of PCNA and p21 100 1/(AU∙min) 0.001 
𝑘RbE2F
As  association of Rb and E2F 5 1/(AU∙min) 0.34 
𝑘RcPc
As  association of primed RCs and PCNA 0.01 1/(AU∙min) 0.45 
𝑘Ca
De constitutive CycA degradation 0.01 1/min 0.15 
𝑘Ca,C1
De  APC/CCdh1-mediated CycA degradation 2 1/(AU∙min) 0.16 
𝑘Ce
De constitutive CycE degradation 0.004 1/min 0.89 
𝑘Ce,Ca
De  CycA:Cdk2-mediated CycE degradation 0.015 1/(AU∙min) 0.48 
𝑘E1
De constitutive Emi1 degradation 0.0005 1/min 0.002 
𝑘E1,𝐶1
De  APC/CCdh1-mediated Emi1 degradation 0.005 1/min 0.01 
𝑘E2F
De  constitutive E2F degradation 0.05 1/min 10.55 
𝑘P21
De  constitutive p21 degradation 0.0025 1/min 0.05 
𝑘P21,Cy
De  cyclin:Cdk2-mediated p21 degradation 0.007 1/(AU∙min) 0.14 
𝑘P21,𝑅𝐶𝑎
De  RCa-mediated p21 degradation 1 1/(AU∙min) 0.005 
𝑘P53
De  DNA damage-dependent p53 degradation 0.05 AU/min 0.02 
𝑘Pr
De constitutive degradation of Cdh1-activity probe 0.0001 1/min 1∙10-5 
𝑘C1
Dp
 dephosphorylation of APC/CCdh1 0.05 1/min 0.17 
𝑘Rb
Dp
 dephosphorylation of Rb 0.05 1/min 3.61 
𝑘Rc
Dp
 dephosphorylation of primed RCs 0.05 1/min 0.2 
𝑘CyP21
Ds  dissociation of cyclin:Cdk2:p21 complexes 0.05 1/min 0.001 
𝑘E1C1
Ds  dissociation of Emi1:APC/CCdh1 complexes 0.01 1/min 1∙10-5 
𝑘PcP21
Ds  dissociation of PCNA:p21 complexes 0.01 1/min 1∙10-4 
𝑘RbE2F
Ds  dissociation of Rb:E2F complexes 0.005 1/min 6∙10-5 
𝑘RcPc
Ds  dissociation of RCp:PCNA complexes 0.001 1/min 0.01 
𝑘Pc
Ex PCNA export from the nucleus 0.006 1/min 0.91 
𝑘Dam
Ge  replication-independent DNA damage 0.001 AU/min 0.01 
𝑘Dam,𝑅𝐶𝑎
Ge  replication-dependent DNA damage 0.012 1/min 0.01 
𝑘Pc
Im PCNA import into the nucleus 0.003 AU/min 1 
𝑘C1
Ph constitutive APC/CCdh1 phosphorylation 0 1/min - 
𝑘C1,Ca
Ph  CycA:Cdk2-mediated APC/CCdh1 phosphorylation 1 1/(AU∙min) 0.01 
𝑘C1,Ce
Ph  CycE:Cdk2-mediated APC/CCdh1 phosphorylation 0.01 1/(AU∙min) 5∙10-4 
𝑘RbCa
Ph  CycA:Cdk2-mediated Rb phosphorylation 0.3 1/(AU∙min) 0.13 
30 
 
𝑘RbCd
Ph  CycD:Cdk4/6-mediated Rb phosphorylation 0.2 1/(AU∙min) 1.33 
𝑘RbCe
Ph  CycE:Cdk2-mediated Rb phosphorylation 0.3 1/(AU∙min) 1.68 
𝑘Rc
Ph cyclin:Cdk2-mediated priming of RCs 0.1 1/min 0.27 
𝑘Dam
Re  p53-independent DNA damage repair 0.001 1/min 0.001 
𝑘Dam,P53
Re  p53-dependent DNA damage repair 0.005 1/min 0.001 
𝑘Ca
Sy
 constitutive CycA synthesis 0.02 1/min 0.52 
𝑘Ce
Sy
 constitutive CycE synthesis 0.01 1/min 2.14 
𝑘Dna
Sy
 DNA synthesis by active RCs 0.0093 1/min 0.73 
𝑘E1
Sy
 constitutive Emi1 synthesis 0.005 1/min 0.26 
𝑘E2F
Sy
 constitutive E2F synthesis 0.03 AU/min 4.94 
𝑘E2F,E2F
Sy
 E2F-dependent E2F synthesis 0.04 AU/min 4.09 
𝑘P21
Sy
 constitutive p21 synthesis 0.002 AU/min 0.14 
𝑘P21,P53
Sy
 p53-dependent p21 synthesis 0.008 1/min 0.02 
𝑘P53
Sy
 constitutive p53 synthesis 0.05 AU/min 0.02 
𝑘Pr
Sy
 constitutive synthesis of Cdh1 activity probe 0.01 AU/min 0.04 
𝑛 hill coefficient for priming of RCs 6 - 0.29 
ain simulations of depletion experiments 
 
Table S2. Non-zero initial conditions of the mathematical model.a 
Variable Description Value Unit 
𝐶𝑎t CycA:Cdk2 level 1.2 AU 
𝐶𝑒t CycE:Cdk2 level 0.5 AU 
𝑃21t total p21 level 0.6 AU 
𝑃𝑐𝑛𝑎a free PCNA in the nucleus 0.5 AU 
𝑅𝑐 pre-replication complexes 1 AU 
aThese values correspond to a newly-born cell. 
 
